• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Tagged: lung cancer

  • David Baldwin MD Nottingham University 0
    • in Audio · AJO · Oncology
    • — 24 Feb, 2020

    CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms

    UK & NETHERLANDS—Following the the AJO Podcast interview with Professor Harry de Koning MD PhD, from the Erasmus University in Rotterdam, who discussed his research published in the New England Journal of Medicine that supports the widespread introduction of computed …

    Read more
    Professor Harry de Koning MD PhD 0
    • in Audio · AJO · Oncology
    • — 7 Feb, 2020

    Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent

    Second Study Confirms Lung Cancer CT Screening Cuts Deaths

    NETHERLANDS—Erasmus University Medical Center, Rotterdam—Research published in the New England Journal of Medicine has confirmed the viability of computed tomographic (CT) screening for detecting cases of lung cancer early in high-risk …

    Read more
  • ALK—Targeted Lung Cancer Drugs Benefited Real World Patients  0
    • in AJO · Audio · Oncology
    • — 7 Nov, 2018

    ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

    MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry …

    Read more
    Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer 0
    • in AJO · Audio · Oncology
    • — 27 Oct, 2018

    Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer

    MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 …

    Read more
  • Lung Cancer 0
    • in AJO · Audio · Oncology
    • — 8 Jun, 2018

    Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer

    CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control …

    Read more
    First-Line Pembrolizumab Boosts Survival in PD-L1-Positive Advanced Lung Cancer 0
    • in AJO · Audio
    • — 2 Jan, 2017

    First-Line Pembrolizumab Boosts Survival in PD-L1-Positive Advanced Lung Cancer

    Audio Journal of Oncology, January 2, 2017

    COPENHAGEN—Patients with metastatic non-small cell lung cancers (NSCLC) expressing the programmed cell-death ligand 1 (PD-L1) protein responded better to initial treatment with the anti-PD-L1 immunotherapy pembrolizumab—and lived longer with fewer toxicities—than to standard …

    Read more
  • PD-L1 Checkpoint Inhibitor Immunotherapy Boosts Survival in Lung Cancer 0
    • in AJO · Audio · Oncology
    • — 6 Dec, 2016

    PD-L1 Checkpoint Inhibitor Immunotherapy Boosts Survival in Lung Cancer

    The Audio Journal of Oncology

    Reporting from the 2016 Congress of the European Society of Medical Oncology

    COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab extended overall survival when compared head-to-head with docetaxel among patients with previously-treated non-small cell …

    Read more
    Lung Cancer—First-Line Checkpoint Inhibitor Combination Benefit 0
    • in AJO · Audio · Oncology
    • — 23 Nov, 2016

    Lung Cancer—First-Line Checkpoint Inhibitor Combination Benefit

    COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced non-squamous non-small-cell lung cancer (NSCLC) and good performance status significantly improved objective response rate (ORR) and progression-free …

    Read more
  • Early Lung Cancer Responds to Preoperative Nivolumab 0
    • in AJO · Audio · Oncology
    • — 17 Nov, 2016

    Early Lung Cancer Responds to Preoperative Nivolumab

    COPENHAGEN—In a phase I study reported at the 2016 congress of the European Society for Medical Oncology (ESMO) six out of 15 patients with resectable early non-small cell lung cancer had “major pathological regression” to neo-adjuvant immunotherapy with nivolumab—the anti-PD1 …

    Read more
    Whole Brain Radiotherapy Does Not Benefit Patients with Brain Metastases from Lung Cancer—European Respiratory Society 2016 Congress 0
    • in AJO · Audio · Oncology
    • — 5 Sep, 2016

    Whole Brain Radiotherapy Does Not Benefit Patients with Brain Metastases from Lung Cancer—European Respiratory Society 2016 Congress

    LONDON, UK—Whole brain radiotherapy brought no benefit to patients whose non-small cell lung cancer had metastasized to the brain in research findings published in The Lancet and presented at the European Respiratory Society (ERS) 2016 Congress held in London (3-7 …

    Read more
  • ASCO Audio Journal of Oncology in Advance -July 1st, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 0
    • in AJO · ASCO · Oncology
    • — 1 Jul, 2007

    ASCO Audio Journal of Oncology in Advance -July 1st, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007

    Christian Manegold
    Christian Manegold
    Roy Herbst
    Roy Herbst

    More Support for Bevacizumab in Advanced Lung Cancer

    REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007
    CHRISTIAN MANEGOLD, Heidelberg University, Mannheim
    COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston

    The benefit of adding bevacizumab
    …
    Read more
    Audio Journal of Oncology in Advance – April 15th, 2007 – Bisphosphonates Recommended for Lung Cancer Bone Metastases 0
    • in ASCO · Oncology
    • — 15 Apr, 2007

    Audio Journal of Oncology in Advance – April 15th, 2007 – Bisphosphonates Recommended for Lung Cancer Bone Metastases

    Peter Harper

    PETER HARPER, Guy’s Hospital, London

    REFERENCE: “Management of Tumour and Treatment Related Symptoms” section, Perspectives in Lung Cancer, Seville
    Bisphosphonates may be more suited for improving the outlook among patients with lung cancer who have bone metastases compared to palliative
    …
    Read more
  • Next Page »
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • Tagged: lung cancer

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.